Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Clinical and functional significance of a novel ferroptosis-related prognosis signature in lung adenocarcinoma.

Clinical and translational medicine

Wang Z, Diao J, Zhao X, Xu Z, Zhang X.
PMID: 33784012
Clin Transl Med. 2021 Mar;11(3):e364. doi: 10.1002/ctm2.364.

No abstract available.

Cite
Wang Z, Diao J, Zhao X, et al. Clinical and functional significance of a novel ferroptosis-related prognosis signature in lung adenocarcinoma. Clin Transl Med. 2021;11(3):e364doi: 10.1002/ctm2.364.
Wang, Z., Diao, J., Zhao, X., Xu, Z., & Zhang, X. (2021). Clinical and functional significance of a novel ferroptosis-related prognosis signature in lung adenocarcinoma. Clinical and translational medicine, 11(3), e364. https://doi.org/10.1002/ctm2.364
Wang, Ziqi, et al. "Clinical and functional significance of a novel ferroptosis-related prognosis signature in lung adenocarcinoma." Clinical and translational medicine vol. 11,3 (2021): e364. doi: https://doi.org/10.1002/ctm2.364
Wang Z, Diao J, Zhao X, Xu Z, Zhang X. Clinical and functional significance of a novel ferroptosis-related prognosis signature in lung adenocarcinoma. Clin Transl Med. 2021 Mar;11(3):e364. doi: 10.1002/ctm2.364. PMID: 33784012; PMCID: PMC7968124.
Copy Download .nbib Format: NLM
Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma.

Journal of cancer research and clinical oncology

Nomura K, Aokage K, Nakai T, Sakashita S, Miyoshi T, Tane K, Samejima J, Suzuki K, Tsuboi M, Ishii G.
PMID: 33811275
J Cancer Res Clin Oncol. 2021 Dec;147(12):3699-3707. doi: 10.1007/s00432-021-03608-4. Epub 2021 Apr 02.

PURPOSE: Lymph node involvement is one of the important prognostic factors of patients with lung adenocarcinoma. In the tumor, node, and metastasis classification, lymph node involvement is categorized only according to the anatomical station and not the involvement pattern....

Cite
Nomura K, Aokage K, Nakai T, et al. Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma. J Cancer Res Clin Oncol. 2021;147(12):3699-3707doi: 10.1007/s00432-021-03608-4.
Nomura, K., Aokage, K., Nakai, T., Sakashita, S., Miyoshi, T., Tane, K., Samejima, J., Suzuki, K., Tsuboi, M., & Ishii, G. (2021). Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma. Journal of cancer research and clinical oncology, 147(12), 3699-3707. https://doi.org/10.1007/s00432-021-03608-4
Nomura, Kotaro, et al. "Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma." Journal of cancer research and clinical oncology vol. 147,12 (2021): 3699-3707. doi: https://doi.org/10.1007/s00432-021-03608-4
Nomura K, Aokage K, Nakai T, Sakashita S, Miyoshi T, Tane K, Samejima J, Suzuki K, Tsuboi M, Ishii G. Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma. J Cancer Res Clin Oncol. 2021 Dec;147(12):3699-3707. doi: 10.1007/s00432-021-03608-4. Epub 2021 Apr 02. PMID: 33811275.
Copy Download .nbib Format: NLM
Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.

Thoracic cancer

Ide M, Tanaka K, Sunami S, Asoh T, Maeyama T, Tsuruta N, Nakanishi Y, Okamoto I.
PMID: 30152594
Thorac Cancer. 2018 Nov;9(11):1519-1521. doi: 10.1111/1759-7714.12853. Epub 2018 Aug 28.

The efficacy and safety of immune-checkpoint inhibitors in non-small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62-year-old man with multiple pleural tumors and carcinomatous pleurisy. High-resolution computed tomography...

Cite
Ide M, Tanaka K, Sunami S, et al. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thorac Cancer. 2018;9(11):1519-1521doi: 10.1111/1759-7714.12853.
Ide, M., Tanaka, K., Sunami, S., Asoh, T., Maeyama, T., Tsuruta, N., Nakanishi, Y., & Okamoto, I. (2018). Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thoracic cancer, 9(11), 1519-1521. https://doi.org/10.1111/1759-7714.12853
Ide, Maako, et al. "Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis." Thoracic cancer vol. 9,11 (2018): 1519-1521. doi: https://doi.org/10.1111/1759-7714.12853
Ide M, Tanaka K, Sunami S, Asoh T, Maeyama T, Tsuruta N, Nakanishi Y, Okamoto I. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thorac Cancer. 2018 Nov;9(11):1519-1521. doi: 10.1111/1759-7714.12853. Epub 2018 Aug 28. PMID: 30152594; PMCID: PMC6209776.
Copy Download .nbib Format: NLM
Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Sharpnack MF, Ranbaduge N, Srivastava A, Cerciello F, Codreanu SG, Liebler DC, Mascaux C, Miles WO, Morris R, McDermott JE, Sharpnack JL, Amann J, Maher CA, Machiraju R, Wysocki VH, Govindan R, Mallick P, Coombes KR, Huang K, Carbone DP.
PMID: 30017829
J Thorac Oncol. 2018 Oct;13(10):1519-1529. doi: 10.1016/j.jtho.2018.06.025. Epub 2018 Jul 11.

INTRODUCTION: Despite apparently complete surgical resection, approximately half of resected early-stage lung cancer patients relapse and die of their disease. Adjuvant chemotherapy reduces this risk by only 5% to 8%. Thus, there is a need for better identifying who...

Cite
Sharpnack MF, Ranbaduge N, Srivastava A, et al. Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma. J Thorac Oncol. 2018;13(10):1519-1529doi: 10.1016/j.jtho.2018.06.025.
Sharpnack, M. F., Ranbaduge, N., Srivastava, A., Cerciello, F., Codreanu, S. G., Liebler, D. C., Mascaux, C., Miles, W. O., Morris, R., McDermott, J. E., Sharpnack, J. L., Amann, J., Maher, C. A., Machiraju, R., Wysocki, V. H., Govindan, R., Mallick, P., Coombes, K. R., Huang, K., & Carbone, D. P. (2018). Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13(10), 1519-1529. https://doi.org/10.1016/j.jtho.2018.06.025
Sharpnack, Michael F, et al. "Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 13,10 (2018): 1519-1529. doi: https://doi.org/10.1016/j.jtho.2018.06.025
Sharpnack MF, Ranbaduge N, Srivastava A, Cerciello F, Codreanu SG, Liebler DC, Mascaux C, Miles WO, Morris R, McDermott JE, Sharpnack JL, Amann J, Maher CA, Machiraju R, Wysocki VH, Govindan R, Mallick P, Coombes KR, Huang K, Carbone DP. Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma. J Thorac Oncol. 2018 Oct;13(10):1519-1529. doi: 10.1016/j.jtho.2018.06.025. Epub 2018 Jul 11. PMID: 30017829; PMCID: PMC7135954.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries